EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSXMAG00000013771
Gene Symbol: CACNA1A
3 Cross references
192 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSXMAG00000013969
Gene Symbol: CACNA1A
3 Cross references
186 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSXMAG00000007358
Gene Symbol: CACNA1B
3 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSXMAG00000011036
Gene Symbol: CACNA1C
3 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSXMAG00000019252
Gene Symbol: CACNA1D
4 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSXMAG00000019132
Gene Symbol: CACNA1E
3 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSXMAG00000022257
Gene Symbol: CACNA1E
2 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSXMAG00000024852
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSXMAG00000010988
Gene Symbol: CACNA1S
3 Cross references
199 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSXMAG00000019720
Gene Symbol: CNR1
4 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSXMAG00000019630
Gene Symbol: CNR1
3 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSXMAG00000013232
Gene Symbol: LOC102231602
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).